The transformation of risk in the Ozempic era
Op-Ed published November 26, 2025
Dr. Laurence B. Mussio argues in The Globe and Mail that Novo Nordisk’s sudden loss in market value following its Ozempic profit warning illustrates a new form of corporate risk: the moment when a successful product becomes social infrastructure. He contends that managing infrastructure-level risk requires historical awareness, proactive engagement with governments, and acceptance of public obligations before regulation is imposed. He asserts that breakthrough innovation does not remove risk; it transforms it — and failure to recognize that transformation can be more destructive than any technical or market misstep.
Posted in About LRI